EcoDrugPlus

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSSLDG00000002006
Gene Symbol: FDFT1
3 Cross references
220 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSSLDG00000022887
Gene Symbol: FNTA
3 Cross references
221 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSSLDG00000022856
Gene Symbol: FGFR1
3 Cross references
204 Possible Orthologues:

Fibroblast Growth Factor Receptor 1-A-Like

Ensembl ID : ENSSLDG00000015118
Gene Symbol: LOC111644951
4 Cross references
209 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSSLDG00000023773
Gene Symbol: FGFR2
3 Cross references
214 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSSLDG00000009653
Gene Symbol: FGFR3
3 Cross references
193 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSSLDG00000004662
Gene Symbol: FLT1
1 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSSLDG00000009892
Gene Symbol: FLT4
3 Cross references
193 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSSLDG00000020972
Gene Symbol: FOLH1B
3 Cross references
339 Possible Orthologues:

Folate Receptor Beta

Ensembl ID : ENSSLDG00000020787
Gene Symbol: FOLR2
3 Cross references
436 Possible Orthologues:

Follicle-Stimulating Hormone Receptor-Like

Ensembl ID : ENSSLDG00000017431
Gene Symbol: LOC111655238
4 Cross references
200 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSSLDG00000021279
Gene Symbol: LOC111668723
2 Cross references
338 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).